Humira was the largest of AbbVie Inc.’s 12 reported lines in fiscal 2017, at $18.43B — 65% of $28.22B.
| Products and Services | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2017 |
|---|---|---|---|---|---|---|
| Humira | $12.54B | $14.01B | $18.43B | |||
| H U M I R A | — | — | — | |||
| Revenue, Net | — | — | — | |||
| Dyslipidemia Products | — | — | — | |||
| Imbruvica | — | $754.00M | $2.57B | |||
| All Other | $1.96B | $1.40B | $998.00M | |||
| Other Products | — | — | — | |||
| Hcv | — | $1.64B | $1.27B | |||
| Androgel | $934.00M | $694.00M | $577.00M | |||
| Andro Gel | — | — | — | |||
| Kaletra | $870.00M | $700.00M | $423.00M | |||
| Lupron | $778.00M | $826.00M | $829.00M | |||
| Synagis | $835.00M | $740.00M | $738.00M | |||
| Synthroid | $709.00M | $755.00M | $781.00M | |||
| Sevoflurane | $550.00M | $474.00M | $410.00M | |||
| Creon | $516.00M | $632.00M | $831.00M | |||
| Duodopa | $220.00M | $231.00M | $355.00M | |||
| Viekira | $48.00M | — | — | |||
| Total | $19.96B | $22.86B | $28.22B |
In fiscal 2017, which ended December 31, 2017, the 12 revenue lines AbbVie Inc. reported in this breakdown added up to $28.22B. That was up 23.4% from $22.86B in fiscal 2015, the latest earlier year this breakdown was reported. Humira was the largest revenue line, at $18.43B or 65.3% of the total, followed by Imbruvica ($2.57B, 9.1%) and Hcv ($1.27B, 4.5%). Together, the two largest revenue lines made up 74.4% of this total.
Compared with fiscal 2015, the latest earlier year reported, Imbruvica grew the fastest, rising 241.2% to $2.57B. All Other fell the most, down 28.8% to $998.00M.
Imbruvica (fiscal 2015) and Hcv (fiscal 2015) were first reported as separate revenue lines during this period. The table also keeps 6 revenue lines that AbbVie Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 6 fiscal years between 2011 and 2017, as reported in AbbVie Inc.'s annual filings.
Calculated Under Revenue Guidance In Effect Before Topic 606 was the largest of AbbVie Inc.’s 2 reported lines in fiscal 2018, at $32.81B — 100% of $32.75B.
| Initial Application Period Cumulative Effect Transition (2) | FY 2018 |
|---|---|
| Calculated Under Revenue Guidance In Effect Before Topic 606 | $32.81B |
| Difference Between Revenue Guidance In Effect Before & After Topic 606 | -$59.00M |
| Total | $32.75B |
In fiscal 2018, which ended December 31, 2018, the 2 revenue lines AbbVie Inc. reported in this breakdown added up to $32.75B. Calculated Under Revenue Guidance In Effect Before Topic 606 was the largest revenue line, at $32.81B or 100.2% of the total.
Figures are shown as reported, so the total is net of Difference Between Revenue Guidance In Effect Before & After Topic 606, which was -$59.00M in fiscal 2018. This breakdown covers every fiscal year from 2018 to 2018, as reported in AbbVie Inc.'s annual filings.
United States was the largest of AbbVie Inc.’s 11 reported lines in fiscal 2017, at $18.25B — 65% of $28.22B.
| Geography | FY 2011 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|
| United States | $10.85B | $13.56B | $15.95B | $18.25B | ||
| Revenue, Net | — | — | — | — | ||
| All Other Countries | $3.90B | $4.00B | $3.89B | $4.08B | ||
| Other Countries | — | — | — | — | ||
| Germany | $1.04B | $1.08B | $1.10B | $1.16B | ||
| United Kingdom | $722.00M | $688.00M | $776.00M | $807.00M | ||
| Japan | $581.00M | $599.00M | $770.00M | $764.00M | ||
| France | $584.00M | $597.00M | $713.00M | $730.00M | ||
| Spain | $534.00M | $618.00M | $589.00M | $521.00M | ||
| Canada | $551.00M | $551.00M | $624.00M | $659.00M | ||
| Italy | $432.00M | $452.00M | $523.00M | $475.00M | ||
| The Netherlands | $345.00M | $334.00M | $352.00M | $362.00M | ||
| Brazil | $435.00M | $376.00M | $355.00M | $410.00M | ||
| Total | $19.96B | $22.86B | $25.64B | $28.22B |
In fiscal 2017, which ended December 31, 2017, the 11 regions AbbVie Inc. reported in this breakdown added up to $28.22B. That was up 10.1% from $25.64B in fiscal 2016. United States was the largest region, at $18.25B or 64.7% of the total, followed by All Other Countries ($4.08B, 14.5%) and Germany ($1.16B, 4.1%). Together, the two largest regions made up 79.1% of this total.
Compared with fiscal 2016, United States grew the fastest, rising 14.4% to $18.25B. Japan fell the most, down 0.8% to $764.00M. Over fiscal 2014 to 2017, revenue across these regions went from $19.96B to $28.22B, a compound annual growth rate of 12.2%. United States' share of the total rose from 54.3% to 64.7% over the same years.
The table also keeps 2 regions that AbbVie Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 6 fiscal years between 2011 and 2017, as reported in AbbVie Inc.'s annual filings.
AbbVie Inc. (ABBV) breaks its revenue down by revenue line and region. In fiscal 2017, its largest revenue line was Humira, with $18.43B or 65.3% of the total, followed by Imbruvica at $2.57B (9.1%).
Humira was AbbVie Inc.'s largest revenue line in fiscal 2017, with $18.43B in revenue, 65.3% of the $28.22B reported across its 12 revenue lines.
United States was AbbVie Inc.'s largest region in fiscal 2017, with $18.25B in revenue, 64.7% of the $28.22B reported across its 11 regions.
Of the AbbVie Inc. regions reported in both fiscal 2016 and fiscal 2017, and making up at least 2% of the total, United States grew the fastest, rising 14.4% from $15.95B to $18.25B.
Every figure is taken from AbbVie Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2011 to 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.